Inogen (NASDAQ:INGN) Now Covered by B. Riley

B. Riley began coverage on shares of Inogen (NASDAQ:INGN - Free Report) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $14.00 price objective on the medical technology company's stock.

Several other analysts have also recently commented on INGN. Needham & Company LLC upgraded Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price on the stock in a research report on Thursday, May 22nd. Wall Street Zen lowered Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th.

Inogen Trading Down 1.8%

Shares of NASDAQ:INGN traded down $0.12 on Monday, hitting $6.48. The company had a trading volume of 289,617 shares, compared to its average volume of 241,821. The company has a market cap of $174.25 million, a PE ratio of -5.63 and a beta of 1.64. The business has a 50 day moving average of $6.66 and a 200 day moving average of $8.30. Inogen has a 52-week low of $5.70 and a 52-week high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The company had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. As a group, equities analysts predict that Inogen will post -1.73 EPS for the current year.

Hedge Funds Weigh In On Inogen

Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its position in shares of Inogen by 35.7% in the first quarter. Acadian Asset Management LLC now owns 1,028,322 shares of the medical technology company's stock worth $7,325,000 after purchasing an additional 270,453 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Inogen by 0.6% in the 4th quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company's stock valued at $7,785,000 after buying an additional 5,148 shares during the period. Bridgeway Capital Management LLC lifted its position in Inogen by 4.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company's stock worth $5,788,000 after buying an additional 28,517 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Inogen by 25.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock valued at $5,574,000 after buying an additional 123,208 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of Inogen by 30.1% during the 1st quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company's stock valued at $4,022,000 after acquiring an additional 130,381 shares in the last quarter. Hedge funds and other institutional investors own 89.94% of the company's stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.